Pipeline Analysis of Herpes Zoster (Shingles) and Therapeutic Development in H1 2017

Published on : May 19, 2017

Albany, New York, May 19, 2017: Weak immune system due to disease, stress, age or any other reason and past history of chickenpox has resulted in the Herpes Zoster or Shingles infectious patients globally. The wrong diagnosis and the major effects on the body of the infected person have directly resulted in the diagnosis of Herpes Zoster and development in its drugs. Market Research Hub (MRH) has detailed the pipeline review of the infection in the report “Herpes Zoster (Shingles) - Pipeline Review, H1 2017” that has been recently added to its massive repository. The study is a detailed pipeline analysis of Herpes Zoster (Shingles) with therapeutic development by companies and the drug used for Herpes Zoster.

Shingles (herpes zoster) is a painful, blistering skin rash caused by the varicella-zoster virus. The various symptoms are headache, joint pain, fever and chills, and swollen glands. Treatment includes antihistamines and pain relievers. Shingles mostly occur when the virus that causes chickenpox starts up again in the body. After a person gets healthier from chickenpox, the virus becomes dormant in the nerve roots; in some cases, it stays dormant forever, in others, the virus "wakes up" when the immune system weakens. Some medicines may also trigger the virus to wake up and cause the infection.

The pipeline review starts with the Herpes Zoster (Shingles) overview and the various therapeutic development and assessment that are currently in progress. This pipeline review has been analyzed by companies and products under development by companies. Further, the therapeutic assessment is completed in the research by the target, mechanism of action (MoA), route of administration and molecule type. The companies involved in therapeutics development of the Herpes Zoster (Shingles) are also listed in the report, the main companies profiled are ContraVir Pharmaceuticals Inc., Epiphany Biosciences Inc., Astellas Pharma Inc., Beijing Minhai Biotechnology Co Ltd., Foamix Pharmaceuticals Ltd., GeneOne Life Science Inc., GlaxoSmithKline Plc, Merck & Co Inc., NAL Pharmaceuticals Ltd., NanoViricides Inc., SK Chemicals Co Ltd., TSRL Inc. and XBiotech Inc.

The pipeline study also provides descriptive drug profiles, with product description, R&D brief, mode of action (MoA) & other developmental activities. The various drugs described in the report are FV-100, acyclovir, amenamevir, GLS-5100, GSK-1437173A, herpes zoster vaccine, monoclonal antibody for Shingles, NAL-3223, NBP-608, NN-001, Small Molecule for Shingles, TSR-087, V-212, and valomaciclovir stearate. Finally, the dormant projects, discontinued projects, and the product development milestone is encapsulated in the research. The various relevant news and press release are also linked with the report for detailed and descriptive pipeline review.

Click here to get more info with TOC in a PDF Format : https://www.marketresearchhub.com/enquiry.php?type=S&repid=1068031

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email : sales@marketresearchhub.com

Back To Top